Amyotrophic Lateral Sclerosis (ALS)

2 protocols meet the specified criteria


A multicenter, 18-week open label safety and efficacy trial of Dalfampridine in primary lateral sclerosis


A Single-Center, Open Label Study to Assess the Safety and Tolerability of Metformin in Subjects with C9orf72 Amyotrophic Lateral Sclerosis over 24 Weeks of Treatment